SkyWest Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? SkyWest Inc trades at $96.52 (market cap $3.75B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: SkyWest Inc is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | SLS | |
|---|---|---|
Market Cap | $3.75B | $2.27B |
Volume | 196,324 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $115.94 | $15.46 |
52-Week Low | $78.40 | $1.39 |
Typical Hold Time | 8 Days | — |
Enterprise Value | $5.54B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $96.73, up 0.09% on the day, with a bearish technical signal but strong fundamentals including a P/E of 9.6 and net income margin of 9.78%. Recent earnings show mixed results, with a Q1 2026 beat but a Q2 2026 miss. The company is expanding its fleet and flying agreements, supporting growth amid cost pressures.
The outlook is cautiously optimistic, with a consensus price target of $112 offering 16% upside. Risks include execution on cost control and competitive pressures, but low valuation and analyst buy ratings suggest potential for recovery if operational trends improve.
No Aura AI signal available yet.
Trailing returns across standard periods
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →